Marinomed Biotech AG (VIE:MARI)

Market Cap	9.00M -74.5%
Revenue (ttm)	7.96M +66.1%
Net Income	18.02M
EPS	9.79
Shares Out	2.00M
PE Ratio	0.46
Forward PE	3.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50
Open	4.500
Previous Close	4.500
Day's Range	4.500 - 4.500
52-Week Range	2.200 - 21.000
Beta	-0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 16, 2026

About Marinomed Biotech AG

Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services. The company was formerly know...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 32
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MARI

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 27, 2026

Data Sources Report a data error